Get Adobe Flash player


Authors: Pereviazkina M.V.

Pages: 237-245


The interactions are observed between the cardiovascular and kidney continuum. Nephroangiosclerosis in patients with cardiovascular pathology is one of the main causes of chronic renal insufficiency (CRI). Cardiovascular diseases are the main cause of mortality in patients with terminal CRI, whereby the cardiovascular mortality in patients dialyzed continuously is several times higher than in general population. Some data suggest that the interaction between the cardiovascular and kidney continuum can be already observed at early stages of HTN. Therefore, an early marker for renal impairment, in particular microalbuminuria, is at present considered to be a cardiovascular risk factor.

The objective of this study was to investigate the microalbuminuria level and endothelial functionin patients with stage II hypertension.

182 patients with stage II hypertension (HTN) were examined. 40 patients with stage II HTN with no sign of other cardiovascular and renal diseases were studied as the control group. The key factor for selection was the absence of MAU in this group ofpatients. 

The cardiac and hemodynamics status, the left ventricular systolic and diastolic functions were assessed using the ULTIMA Pro-30 scanner. The renal ultrasound examination was carried out, albumin excretion in urine (MAU, mg/24 h) was determined by the immunoturbidimetric test using the Micral-Test II test kit (Roche Diagnostics GMBH, Germany), the levels of endothelin-I and NO were determined.

In patients with stage II hypertension in whom microalbuminuria was detected, the discrepancy between the indicators of the left ventricular systolic function as compared with the group of patients in whom albumin excretion was not been observed. The tendency toward deterioration is observed in the indicators showing the left ventricular diastolic function depending on the presence of microalbuminuria. During the study of systemic hemodynamics according to the arterial hypertension stage (as the disease progressed) and the presence of albumin excretion, there was observed a decrease in the indicators, such as systolic discharge, cardiac output, cardiac index and an increase in total peripheral vascular resistance what resulted in increase in workload on the left ventricle myocardium and decrease in its capacity. The obtained data demonstrate the need to determine the albumin level in patients with hypertension in order to slow down the progression of hypertensive nephropathy.

Key words: hypertensive illness, mikroal'buminuriya, early diagnostics, hemodynamics.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

In progress



  1. Ruilope LM, Alcazar JM, Rodicio JL. Renal consequences of arterial hypertension. Journal of Hypertension2009;10(7):85-90.
  2. Lafayette RA. Preventing disease progression in chronic renal failure. American Family Physician2005;52(6):1783–1791.
  3. Moore MA, Epstein M, Agodoa L, Dworkin LD. Current strategies for management of hypertensive renal disease. Archives of Internal Medicine. 2009;159(1):23–28.
  4. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens.Archives of Internal Medicine. 2004;151(9):1761–1265.
  5. Bennett PH, Haffner S, Kasiske BL, KeaneWF, Mogensen CE, Parving HH, Steffes MW, Striker GE. Screening and management of microalbuminuria in patients with diabetes mellitus.American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation2005;25(2):107–112.
  6. Ritz E, Fliser D, Klimm HP. Assessment of cardiovascular risk factors: the role of microalbuminuriaAmsterdam, 2004.
  7. Haffner SM, Stem MP, Gruber KK, Hazuda HP, Mitchell BD, PattersonJK. Microalbuminuria. Potential marker for increased cardiovascular risk factors on nondiabetic subjects? Arteriosclerosis,2009;10(5):727–731.
  8. Bigazzi R, Bianchi S, Baldari D, CampeseJournal ofHypertension2007;16(9):1325–1333.